Mechanistic and anti-proliferative studies of two novel, biologically active bis-benzimidazoles

European Journal of Cancer

Volumn 39, Issue 17, 2003, Pages 2548-2555

  Seaton, A ^a   Higgins, C ^a   Mann, J ^a   Baron, A ^a   Bailly, C ^b   Neidle, S ^c   Van Den Berg, H ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b INSERM   (France)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

bis Benzimidazoles; DNA minor groove binders; Topoisomerase

Indexed keywords

ABA 13; ABA 833; BENZIMIDAZOLE DERIVATIVE; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CATALYSIS; CELL ACTIVITY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL POPULATION; CELL PROLIFERATION; CELL STRAIN MCF 7; COLON CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DETERMINATION; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME INACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INHIBITION KINETICS; KINETOPLAST; PLASMID; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0242331200     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00621-X     Document Type: Article

References (22)

1. Reddy B.S.P., Sondhi S.M., Lown J.W. Synthetic DNA minor groove-binding drugs. Pharmacol. Ther. 84:1999;1-111.
2. D'Incalci M., Sessa C. DNA minor groove binding ligands. a new class of anticancer agents Exp Opin Invest Drugs. 6:1997;875-884.
3. Li L.H., Swenson D., Schpock S., Kuentzel S., Dayton B., Kreiger W. CC-1065 (NSC-298223) a novel antitumour agent that interacts strongly with double stranded DNA. Cancer Res. 42:1982;999-1004.
4. Neidle S. DNA minor-groove recognition by small molecules. Nat. Prod. Rep. 18:2001;291-309.
5. Neidle S., Mann J., Rayner E.L.et al. Symmetric bis-benzimidazoles: new sequence-selective DNA binding molecules. J. Chem. Soc. Chem. Commun. 929-930:1999.
6. Lammler G., Herzog H., Saupe E., Schutze H.R. Chemotherapeutic studies on Litomosodoides carini infection of Mastomys nataleusis 1. The filaricidal action of 2,6-bis-benzimidazoles. WHO Bull. 44:1971;751-756.
7. Kraut E.H., Masspeis L., Bakerzak S., Grever M. Evaluation of Pibenzimol (NSC322921) in refractory solid malignancies. Proc Am Soc Clin Oncol. 7:1988;62.
8. Kraut E., Fleming T., Segal M., Neidhartm J., Behrans B.C., MacDonald J. Phase II study of Pibenzimol in pancreatic cancer - a Southwest Oncology Group study. Invest New Drugs. 9:1999;95-96.
9. Mann J., Baron A., Opoku-Boahen Y.et al. A new class of symmetric bisbenzimidazole-based DNA minor groove-binding agents showing antitumour activity. J. Med. Chem. 44:2001;138-144.
10. Marini J.C., Miller K.G., Englund P.T. Decatenation of kinetoplast DNA by topoisomerases. J. Biol. Chem. 255:1980;4976-4979.
11. Bailly C. DNA relaxation and cleavage assays to study topoisomerase I inhibitors. Methods Enzymol. 340:2001;610-623.
12. Morgan S.A., Watson J.V., Twentyman P.R., Smith P.J. Reduced nuclear binding of a DNA minor groove ligand (Hoechst 3342) and its impact on cytotoxicity in drug resistant murine cell lines. Br.J Cancer. 62:1990;959-965.
13. Sharma N., Ramachandran S., Bowers M.et al. Multiple factors other than p53 influence colon cancer sensitivity to paclitaxel. Cancer Chemother Pharmacol. 46:2000;329-337.
14. Corbett A.H., Osheroff N. When good enzymes go bad. conversion of topoisomerase II to a cellular toxin by antineoplastic drugs Chem. Res. Toxicol. 6:1993;585-597.
15. Froelich-Ammon S.J., Osheroff N. Topoisomerase poisons. harnessing the dark side of enzyme mechanism J. Biol. Chem. 270:1995;21429-21432.
16. Pommier Y., Leteurtre F., Fesen M.R.et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 12:1994;530-542.
17. Osheroff N. Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol. Ther. 41:1989;223-241.
18. Berger J.M., Gamblin S.J., Harrison S.C., Wang J.C. Structure and mechanism of DNA topoisomerase II. Nature. 379:1996;225-232.
19. Kim S.A., Kwon Y., Kim J.H., Muller M.T., Chung I.K. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, Berberrubine. Biochemistry. 37:1998;16316-16324.
20. Smith P.J., Souès S., Gottlieb T.et al. Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells. Br J Cancer. 70:1994;914-921.
21. Jones C.B., Clements M.K., Wasi S., Daoud S.S. Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells. Cancer Chemother Pharmacol. 40:1997;475-483.
22. Soderlind K.J., Gorodesky B., Singh A.K., Bachur N.R., Miller G.G., Lown J.W. Bis-benzimidazole anti-cancer agents. targeting human tumour helicases Anti-Cancer Drug Des. 14:1999;19-36.